Your session is about to expire
← Back to Search
Message + Financial Incentive for Booster Dose
N/A
Waitlist Available
Research Sponsored by University of Southern California
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 weeks
Awards & highlights
Study Summary
The goal of this work is to understand whether small financial incentives and messaging can increase the take-up of COVID-19 boosters among patients empaneled at a county public health system. The motivation for this work is the relatively low take-up of COVID-19 boosters. In California, where our experiment is based, only 59% of the population has been boosted, with only 13% receiving the recommended bivalent booster (State of California, 2022).
Eligible Conditions
- Booster Dose
- Booster Message + Financial Incentive
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 2 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 weeks
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Vaccine booster
Trial Design
3Treatment groups
Experimental Treatment
Placebo Group
Group I: Message OnlyExperimental Treatment1 Intervention
Email or SMS Booster Vaccination Reminder
Group II: Message + Financial IncentiveExperimental Treatment2 Interventions
Email or SMS Booster Vaccination Reminder + Offer of a financial incentive for getting boosted in the next 2 weeks.
Group III: ControlPlacebo Group1 Intervention
No message or financial incentive
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Messaging
2022
N/A
~79480
Financial Incentive
2016
N/A
~133420
Find a Location
Who is running the clinical trial?
University of Southern CaliforniaLead Sponsor
916 Previous Clinical Trials
1,546,931 Total Patients Enrolled
J-PAL North AmericaUNKNOWN
1 Previous Clinical Trials
69,972 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger